Plant Name: Ammi majus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| MAPK1; | |
| NR0B1; | |
| NR3C1; | |
| HIF1A; | |
| SLC6A3; SLC6A2; SLCO1B3; SLCO1B1; | |
| PAX8; RAB9A; NPC1; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 0 group B | NR0B1 | Nuclear receptor subfamily 0 group B member 1 | P51843 | CHEMBL1795094 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLC6A3 | Dopamine transporter | Q01959 | CHEMBL238 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.448E-15 | 1.186E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.161E-13 | 7.213E-09 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 9.937E-13 | 7.213E-09 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.974E-12 | 2.661E-08 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.829E-11 | 5.858E-08 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.118E-11 | 1.238E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.125E-10 | 2.042E-07 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NPC1, NR0B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.474E-10 | 3.847E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.080E-10 | 7.375E-07 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.868E-09 | 2.141E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.434E-09 | 2.524E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.427E-09 | 4.191E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.018E-09 | 8.182E-06 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 3.865E-08 | 2.902E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.322E-07 | 8.999E-05 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 1.126E-06 | 5.979E-04 | CYP2A13, CYP2A6 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 3.027E-06 | 1.465E-03 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, RAB9A |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.375E-06 | 1.564E-03 | CYP2D6, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0005330; dopamine:sodium symporter activity | 3.375E-06 | 1.564E-03 | SLC6A2, SLC6A3 |
| BP | GO:0023052; signaling | GO:0051583; dopamine uptake involved in synaptic transmission | 1.684E-05 | 6.323E-03 | SLC6A2, SLC6A3 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.033E-11 | 5.528E-09 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 9.961E-11 | 5.528E-09 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.037E-10 | 7.537E-09 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.097E-08 | 5.819E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.833E-07 | 1.295E-05 | CYP2C9; CYP2A6; CYP1A2; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.182E-06 | 9.587E-05 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.446E-05 | 7.557E-04 | SLCO1B1; SLCO1B3; CYP3A4 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.191E-04 | 5.169E-03 | PAX8; MAPK1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.792E-03 | 1.632E-02 | MAPK1; HIF1A |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.057E-03 | 1.173E-02 | CYP2A6; CYP3A4 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.912E-03 | 1.632E-02 | CYP2C9; CYP2C19 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.163E-03 | 1.649E-02 | MAPK1; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.675E-03 | 1.632E-02 | CYP1A2; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.228E-03 | 1.649E-02 | MAPK1; HIF1A |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.981E-03 | 3.379E-02 | MAPK1; HIF1A |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.916E-03 | 4.440E-02 | PAX8; MAPK1; HIF1A |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.175E-03 | 3.379E-02 | MAPK1; HIF1A |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.999E-03 | 4.440E-02 | CYP2C9; CYP2A6; CYP1A2; CYP2C19; CYP3A4 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.736E-03 | 4.154E-02 | MAPK1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 9.364E-03 | 4.950E-02 | LMNA; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.048E-05 | 1.662E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Non-infectious rhinitis | NA | NR3C1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; NR3C1; NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | SLC6A2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NR3C1; NR3C1; NR3C1; NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; HIF1A; NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | SLC6A2; CYP3A4; NR3C1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; HIF1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1 |